Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model

Gopi Shah; Punitkumar R. Bhatt; Mehul Chorawala; Gaurang Shah

doi:10.52794/hujpharm.1673921

Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model

Abstract

Liver injury is closely associated with changes in gut microbiota, leading to the release of bacterial endotoxins such as lipopolysaccharide (LPS). These endotoxins interact with toll-like receptors (TLRs), especially TLR4, expressed on liver immune cells. Although LPS is known to play a crucial role in liver pathogenesis, the progression of liver dysfunction following LPS exposure remains insufficiently explored. This study aimed to develop and characterize a rat model of LPS-induced liver injury. Animals were divided into five groups (n=6). Group I received saline (control), Group II received alcohol (1.24%, 0.4 ml), and Groups III–V were sensitized with increasing doses of LPS (1 μg, 10 μg, and 100 μg/rat, i.p.) for 10 days and challenged on day 21, with LPS (10 μg/rat, i.p.) which markedly increased the liver parameters. Biochemical parameters like SGPT, SGOT, ALP, bilirubin, total protein, globulin, and albumin were evaluated at multiple time points. Groups III and IV showed significant increased in AST, ALT and ALP level. The protein levels were significantly reduced in alcohol treated group. Bilirubin level was significantly increased in LPS treated and alcohol treated groups around 28th day of treatment, which indicates liver injury. This model demonstrates a reproducible method to study LPS-induced liver damage.

Keywords

Supporting Institution

K.B.Institute of pharmaceutical Education and Research

Project Number

KBIPER/11/276

Ethical Statement

Lipopolysaccharide-induced chronic liver injury model

References

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. NatImmunol.2010;11(5):373–384. doi:10.1038/ni.1863
2.Bihl F, Salez L, Beaubier M, Torres D, Larivière L, et al. Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol. 2003; 170(12): 6141–50. https://doi.org/10.4049/jimmunol.170.12.6141
3.Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, et al. Hepatic fibrosis and cirrhosis: The (myo) fibroblastic cell subpopulations involved. Int J Biochem Cell Biol.2006;38(2):135-151. https://doi.org/10.1016/j.biocel.2005.08.021
4.Ganey P E, Roth R A. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicol. 2001;169(3):195–208.https://doi.org/1016/S0300-483X(01)00523-6
5.Yee S B, Kinser S, Hill D A, et al. Synergistic hepatotoxicity from coexposure to bacterial endotoxin and the pyrrolizidine alkaloid monocrotaline. Toxicol Appl Pharmacol. 2000;166(3):173–185.10. https://doi.org/1006/taap.2000.8968.
6. Zhang D. Tumour necrotic factor (TNF) in the pathogenesis of liver necrosis in viral hepatitis and strategy for its prevention and treatment. Zhonghua Yi Xue Za Zhi. 1990;70(8):438–441.[PubMed PMID: 2174282]
7. Vodovotz Y, Liu S, McCloskey C, et al. The hepatocyte as a microbial product-responsive cell. J Endotoxin Res. 2001;7(5):365–373.https://doi.org/10.1179/096805101101532936.
8. Soares J B, Pimentel-Nunes P, Roncon-Albuquerque R, et al. The role of lipopolysaccharide/ Toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int. 2010;4(4):659–672.https://doi.org/10.1007/s12072-010-9219.

9. Lee YS, Kim YH, Jung YS, et al. Hepatocyte Toll-like receptor 4 mediates lipopolysaccharide-induced hepcidin expression. Exp Mol Med. 2017;49(12):408–409.https://doi.org/10.1038/emm.2017.207.
10. Ibrahim ZA, Armour CL, Phipps S, et al. RAGE and TLRs: relatives, friends or neighbours? Mol Immunol. 2013;56(4):739–744.https://doi.org/10.1016/j.molimm.2013.07.008.
11. Kazuhiko N, Hayate S, Sakaguchi M, Miruno F, Muramatsu et al. Advances in Understanding Lipopolysaccharide-Mediated Hepatitis: Mechanisms and Pathological Features. Curr. Issues Mol. Biol. 2025;47:79 https://doi.org/10.3390/cimb47020079.
12. Cornell RP. Endogenous gut-derived bacterial endotoxin tonically primes pancreatic secretion of insulin in normal rats. Diabetes. 1985;34(12):1253–1259.https://doi.org/10.2337/diab.34.12.1253.
13. Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med. 2007;13(11):1324–32. https://doi.org/10.1038/nm1663.
14. Sherlock S, Dooley J. Diseases of the liver and biliary system. 11th ed. Oxford: Blackwell Science; 2002. https://doi.org/10.1002/9781444341294.
15. Wu H, Wang, Y, Yao Q, Fan L, Meng L et al.. Alkaline phosphatase attenuates LPS-induced liver injury by regulating the miR-146a-related inflammatory pathway. Int. Immunopharmacol. 2021;101(Pt A):108149. https://doi.org/10.1016/j.intimp.2021.108149.
16. Kazunori K, Toru K, Jun I, Masashi Y, Hiromi K et al. The cytoprotective role of lipopolysaccharide-induced nitric oxide against liver damage during early phase of endotoxemia in rats. Shock 2000:14(2):229-233.https://doi.org/10.1097/00024382-200014020-00025.
17. Ganz M, Csak T, Nath B, Szabo G. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol. 2011;17(43):4772-4778. doi:10.3748/wjg.v17.i43.4772.
18. DW R, Loo A T, Levine R A. AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci. 1998;43(9):2156-2159. doi:10.1023/a:1018888021118.
19. Williams A L, Hoofnagle J H. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterol. 1988;95(3):734-739. doi:10.1016/s0016-5085(88)80022-2.
20. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol. 2010;16(11):1321-1329. doi:10.3748/wjg.v16.i11.1321.
21. Schaffert C S, Duryee M J, Hunter C D, et al. Alcohol metabolites and lipopolysaccharide: roles in the development and/or progression of alcoholic liver disease. World J Gastroenterol. 2009;15(10):1209-1218. doi:10.3748/wjg.15.1209.
22. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol. 2009;50(6):1258-1266. doi:10.1016/j.jhep.2009.03.007.
23. Ramírez-Mejía M M, Castillo-Castañeda S M, Pal S C, Qi X, Méndez-Sánchez N. The Multifaceted Role of Bilirubin in Liver Disease: A Literature Review. J Clin Transl Hepatol. 2024;12(11):939-948. doi:10.14218/JCTH.2024.00156.
24. Koteish A, Yang S, Lin H, Huang X, Diehl AM. Chronic ethanol exposure potentiates lipopolysaccharide liver injury despite inhibiting Jun N-terminal kinase and caspase 3 activation. J Biol Chem. 2002;277(15):13037-13044. doi:10.1074/jbc.M101632200

Details

Primary Language

English

Subjects

Basic Pharmacology

Journal Section

Research Article

Authors

Gopi Shah ^*
0000-0001-8299-3509
India

Punitkumar R. Bhatt
0000-0001-6324-051X
India

Mehul Chorawala
0000-0002-3724-0986
India

Gaurang Shah This is me
0000-0003-0769-3914
India

Publication Date

September 1, 2025

Submission Date

April 15, 2025

Acceptance Date

August 15, 2025

Published in Issue

Year 2025 Volume: 45 Number: 3

DOI

https://doi.org/10.52794/hujpharm.1673921

IZ

https://izlik.org/JA29PC43TP

Cite

RIS / Bibtex

APA

Shah, G., Bhatt, P. R., Chorawala, M., & Shah, G. (2025). Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model. Hacettepe University Journal of the Faculty of Pharmacy, 45(3), 223-230. https://doi.org/10.52794/hujpharm.1673921

AMA

1.Shah G, Bhatt PR, Chorawala M, Shah G. Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model. HUJPHARM. 2025;45(3):223-230. doi:10.52794/hujpharm.1673921

Chicago

Shah, Gopi, Punitkumar R. Bhatt, Mehul Chorawala, and Gaurang Shah. 2025. “Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model”. Hacettepe University Journal of the Faculty of Pharmacy 45 (3): 223-30. https://doi.org/10.52794/hujpharm.1673921.

EndNote

Shah G, Bhatt PR, Chorawala M, Shah G (September 1, 2025) Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model. Hacettepe University Journal of the Faculty of Pharmacy 45 3 223–230.

IEEE

[1]G. Shah, P. R. Bhatt, M. Chorawala, and G. Shah, “Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model”, HUJPHARM, vol. 45, no. 3, pp. 223–230, Sept. 2025, doi: 10.52794/hujpharm.1673921.

ISNAD

Shah, Gopi - Bhatt, Punitkumar R. - Chorawala, Mehul - Shah, Gaurang. “Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model”. Hacettepe University Journal of the Faculty of Pharmacy 45/3 (September 1, 2025): 223-230. https://doi.org/10.52794/hujpharm.1673921.

JAMA

1.Shah G, Bhatt PR, Chorawala M, Shah G. Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model. HUJPHARM. 2025;45:223–230.

MLA

Shah, Gopi, et al. “Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model”. Hacettepe University Journal of the Faculty of Pharmacy, vol. 45, no. 3, Sept. 2025, pp. 223-30, doi:10.52794/hujpharm.1673921.

Vancouver

1.Gopi Shah, Punitkumar R. Bhatt, Mehul Chorawala, Gaurang Shah. Exploring the Mechanisms of Lipopolysaccharide-Induced Liver Damage in a Rat Model. HUJPHARM. 2025 Sep. 1;45(3):223-30. doi:10.52794/hujpharm.1673921